CoChat

A holistic approach to targeting disease with polymeric nanoparticles

Open access

The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.

Abstract

The primary goal of nanomedicine is to improve clinical outcomes. To this end, targeted nanoparticles are engineered to reduce non-productive distribution while improving diagnostic and therapeutic efficacy. Paradoxically, as this field has matured, the notion of targeting has been minimized to the concept of increasing the affinity of a nanoparticle for its target. This Opinion article outlines a holistic view of nanoparticle targeting, in which the route of administration, molecular characteristics and temporal control of the nanoparticles are potential design variables that must be considered simultaneously. This comprehensive vision for nanoparticle targeting will facilitate the integration of nanomedicines into clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrd4503

Cites

135 of 135 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 135 references

Research works printed but not linked: 5

  1. Bertrand N Leroux JC The journey of a drug-carrier in the body: an anatomo-physiological perspective Journal of Controlled Release: Official Journal of the Controlled Release Society 161 152 163 2012 22001607
  2. Davis ME Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Nature 464 1067 U140 2010 20305636 PMC2855406
  3. Wang YC Sustained intraspinal delivery of neurotrophic factor encapsulated in biodegradable nanoparticles following contusive spinal cord injury Biomaterials 29 4546 4553 2008 18774604
  4. Kaur IP Kakkar S Nanotherapy for posterior eye diseases Journal of Controlled Release: Official Journal of the Controlled Release Society 2014 24862316
  5. Li H A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres Experimental Eye Research 83 824 833 2006 16822505

Cited by

Items 401–492 of 492

Metadata

Authors
Cheng, C. J., Tietjen, G. T., Saucier-Sawyer, J. K., & Saltzman, W. M.
Affiliations
Yale University (US)
Corresponding author
Saltzman, W. Mark
Venue
Nature Reviews Drug Discovery
Published
2015-01-19
Volume
14
Issue
4
Pages
239-247
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W2041271505
Cited by
480
References
135
Citations by year
2026: 13 · 2025: 37 · 2024: 31 · 2023: 41 · 2022: 42 · 2021: 37 · 2020: 42 · 2019: 40 · 2018: 46 · 2017: 63 · 2016: 60 · 2015: 27
FWCI
3.94
Type
journal article
Language
en
Update notices
erratum (2015-04-30)
Open access
Licence
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute (T32HL007974)
  • National Cancer Institute (R01CA149128, F32CA174247, CA149128)
  • National Institute of Allergy and Infectious Diseases (R01AI112443, T32AI089704, AI106992, R56AI106922, AI112443)
  • National Institute of Biomedical Imaging and Bioengineering (EB00487, R01EB000487)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
targeted drug delivery, polymeric nanoparticles, nanomedicine, nanoparticle targeting, route of administration, nanoparticle design, clinical translation
MeSH terms
Animals, Humans, Polymers, Drug Delivery Systems, Nanomedicine, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.